Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and Ruxolitinib in CML and Ph+ ALL
NCT02253277Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in chronic myeloid leukemia (CML) and Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Novartis. Primary endpoint: Occurrence of dose limiting toxicities at Day 28. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT02253277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253277.